青蒿琥酯肝动脉灌注对原发性肝癌患者免疫功能的影响
|
摘要
本文主要从文献、临床研究方面对青蒿琥酯联合介入治疗对原发性肝癌患者免疫功能的影响进行初步的观察、归纳和总结。
背景:中医认为本病乃由七情、劳倦内伤、外感六淫、饮食不洁,脏腑虚损、气血不和,导致气滞血瘀、痰气凝聚日久而成。与体内“正气不足”和外来的“邪气滞留”有关。现代医学对原发性肝癌的定义、流行病学、病因、临床分型分期、治疗等方面进行了大量的讨论。原发性肝癌可发生于任何年龄,多见于以40～49岁的中壮年,男女之比约为2-5:1。以其发病隐匿、发展迅速、预后极差而严重危害着人类健康,对该病的防治是重要的医学及社会课题。中医药应用于原发性肝癌的治疗己有较多的尝试,经肝动脉灌注中药制剂就是其中一种方法,常可起到与TACE常规方案相同或更高的治疗效果,且毒副作用较小。因此,为提高肝癌的介入治疗效果,研制高效低毒的抗癌中药,尤其是将中药有效成分或复方应用于肝癌介入治疗的研究越来越引起重视。
目的:观察青蒿琥酯介入治疗原发性肝癌的疗效和对患者免疫功能的影响。探索临床新的抗肿瘤中药,以提高中药介入治疗原发性肝癌的疗效,减低介入治疗的副作用和提高机体免疫力。
方法:本研究根据1991年中华人民共和国卫生部医政司编著的《中国常见恶性肿瘤诊治规范》关于原发性肝癌的诊断标准及UICC肝癌1997年TNM分期标准,选取在2007年3月—2008年4月在广州市中医医院肿瘤科诊断为原发性肝癌的患者,在临床观察中,选取60例符合纳入标准者,随机分治疗组30例和对照组30例。两组均给予必要的一般输液和对症治疗,治疗组在运用TACE常规治疗方案的同时,加用青蒿琥酯灌注。对照组采用TACE常规方案治疗。一个疗程后根据瘤体变化、AFP的变化、免疫功能指标及肝、肾功能、白细胞的变化,采用SPSS12.0统计软件包进行分析处理。
结果:治疗组在提高机体免疫力方面明显优于对照组(P＜0.05)。在缩小瘤体、降低AFP近期疗效方面两组大致相似(P＞0.05)。在介入副作用方面,两组未见明显差异(P＞0.05)。
结论:青蒿琥酯联合介入治疗能提高原发性肝癌患者的机体免疫力,但存在增加对肝功能损害的风险,对于开展青蒿琥酯临床抗肿瘤的研究有一定的意义。
This article from the literature and clinical research on Artesunate combined with interventional therapy treatment of patients with primary liver cancer,To observe the fluence of immune function and then summed up and concluded.
Background:The Chinese medicine thought that this sickness is by the seven emotions,the weary internal injury,the external disease factors excesses of the six factors,eating unclean,the internal organs empty damage,the vitality disagreement,will cause the stagnation of flow of vital energy blood stasis,the mental disorder to condense will become in the course of time."The healthy tendency is insufficient" and external "the perverse trend detention" with in vivo concerns。The modern medicine to the primary liver cancer's from the definition、the epidemiology、etiology、clinical-stage、treatment and other aspects has carried ona great deal of discussion。Primary liver cancer can occur at any age。Misprision of its incidence、rapid development、poor prognosis and seriously endanger human health,to prevent and treat the disease is one of the most important medical and social issues。Chinese medicine used in the treatment of primary liver cancer have been more attempts,by the hepatic artery infusion Traditional Chinese Medicine is one of the methods,it often can play a conventional TACE with the same or a higher treatment result and make side effects smaller。Therefore, in order to increase the involvement of liver cancer treatment result, the development of high efficiency and low toxicity of anti-cancer traditional Chinese medicine,particularly applies the traditional Chinese medicine effective component or the compound prescription in liver cancer involves the treatment the research to cause more and more attention。
Objective:To investigate the effect of Artesunate combined with interventional treatment of primary liver cancer and the influences of the immune function in patients。Try to Explores the clinical new anti-tumor traditional Chinese medicine,enhances the traditional Chinese medicine involvement treatment primary liver cancer's curative effect,decreases the involvement treatment the side effects and enhances organism immunity。
Method:The study under the People's Republic of China Ministry of Health for medical Secretary of the "Chinese cancer diagnosis and treatment of common standards" on the diagnostic criteria for primary liver cancer in 1991 and liver cancer in 1997 UICC TNM classification standards,selected 60 patients who has been diagnosised for primary liver cancer that treatment in Tumor inpatient department Of Chinese Medicine hospitals in Guangzhou from March 2007 to April 2008,were randomly divided into 30 cases of the treatment group and control group of 30 cases。Two groups give the essential general infusion and the just right for the illness treatment,The treatment group uses the TACE convention plan treatment,combined Artesunate perfusion。The control group uses the TACE convention plan treatment。After a treatment course, acts according to the tumor size change、the AFP change、the immune function target and the liver、the kidney function、white blood cell's change,uses the SPSS12.0 statistics software package to carry on the analysis processing。
Results:The treatment group increase in immunity obviously better than the control group(P＜0.05);In narrowing the tumor and reducing effect of AFP broadly similar in both groups(P＞0.05);Intervention in the side-effects,There are not seen the obvious difference between Two groups(P＞0.05)。
Conclusion:Artesunate combined intervention therapy can improve patients with primary liver cancer in the body immunity,increase the involvement of liver damage.To Artesunate anti-tumor clinical research have a certain significance。
背景:中医认为本病乃由七情、劳倦内伤、外感六淫、饮食不洁,脏腑虚损、气血不和,导致气滞血瘀、痰气凝聚日久而成。与体内“正气不足”和外来的“邪气滞留”有关。现代医学对原发性肝癌的定义、流行病学、病因、临床分型分期、治疗等方面进行了大量的讨论。原发性肝癌可发生于任何年龄,多见于以40～49岁的中壮年,男女之比约为2-5:1。以其发病隐匿、发展迅速、预后极差而严重危害着人类健康,对该病的防治是重要的医学及社会课题。中医药应用于原发性肝癌的治疗己有较多的尝试,经肝动脉灌注中药制剂就是其中一种方法,常可起到与TACE常规方案相同或更高的治疗效果,且毒副作用较小。因此,为提高肝癌的介入治疗效果,研制高效低毒的抗癌中药,尤其是将中药有效成分或复方应用于肝癌介入治疗的研究越来越引起重视。
目的:观察青蒿琥酯介入治疗原发性肝癌的疗效和对患者免疫功能的影响。探索临床新的抗肿瘤中药,以提高中药介入治疗原发性肝癌的疗效,减低介入治疗的副作用和提高机体免疫力。
方法:本研究根据1991年中华人民共和国卫生部医政司编著的《中国常见恶性肿瘤诊治规范》关于原发性肝癌的诊断标准及UICC肝癌1997年TNM分期标准,选取在2007年3月—2008年4月在广州市中医医院肿瘤科诊断为原发性肝癌的患者,在临床观察中,选取60例符合纳入标准者,随机分治疗组30例和对照组30例。两组均给予必要的一般输液和对症治疗,治疗组在运用TACE常规治疗方案的同时,加用青蒿琥酯灌注。对照组采用TACE常规方案治疗。一个疗程后根据瘤体变化、AFP的变化、免疫功能指标及肝、肾功能、白细胞的变化,采用SPSS12.0统计软件包进行分析处理。
结果:治疗组在提高机体免疫力方面明显优于对照组(P＜0.05)。在缩小瘤体、降低AFP近期疗效方面两组大致相似(P＞0.05)。在介入副作用方面,两组未见明显差异(P＞0.05)。
结论:青蒿琥酯联合介入治疗能提高原发性肝癌患者的机体免疫力,但存在增加对肝功能损害的风险,对于开展青蒿琥酯临床抗肿瘤的研究有一定的意义。
This article from the literature and clinical research on Artesunate combined with interventional therapy treatment of patients with primary liver cancer,To observe the fluence of immune function and then summed up and concluded.
Background:The Chinese medicine thought that this sickness is by the seven emotions,the weary internal injury,the external disease factors excesses of the six factors,eating unclean,the internal organs empty damage,the vitality disagreement,will cause the stagnation of flow of vital energy blood stasis,the mental disorder to condense will become in the course of time."The healthy tendency is insufficient" and external "the perverse trend detention" with in vivo concerns。The modern medicine to the primary liver cancer's from the definition、the epidemiology、etiology、clinical-stage、treatment and other aspects has carried ona great deal of discussion。Primary liver cancer can occur at any age。Misprision of its incidence、rapid development、poor prognosis and seriously endanger human health,to prevent and treat the disease is one of the most important medical and social issues。Chinese medicine used in the treatment of primary liver cancer have been more attempts,by the hepatic artery infusion Traditional Chinese Medicine is one of the methods,it often can play a conventional TACE with the same or a higher treatment result and make side effects smaller。Therefore, in order to increase the involvement of liver cancer treatment result, the development of high efficiency and low toxicity of anti-cancer traditional Chinese medicine,particularly applies the traditional Chinese medicine effective component or the compound prescription in liver cancer involves the treatment the research to cause more and more attention。
Objective:To investigate the effect of Artesunate combined with interventional treatment of primary liver cancer and the influences of the immune function in patients。Try to Explores the clinical new anti-tumor traditional Chinese medicine,enhances the traditional Chinese medicine involvement treatment primary liver cancer's curative effect,decreases the involvement treatment the side effects and enhances organism immunity。
Method:The study under the People's Republic of China Ministry of Health for medical Secretary of the "Chinese cancer diagnosis and treatment of common standards" on the diagnostic criteria for primary liver cancer in 1991 and liver cancer in 1997 UICC TNM classification standards,selected 60 patients who has been diagnosised for primary liver cancer that treatment in Tumor inpatient department Of Chinese Medicine hospitals in Guangzhou from March 2007 to April 2008,were randomly divided into 30 cases of the treatment group and control group of 30 cases。Two groups give the essential general infusion and the just right for the illness treatment,The treatment group uses the TACE convention plan treatment,combined Artesunate perfusion。The control group uses the TACE convention plan treatment。After a treatment course, acts according to the tumor size change、the AFP change、the immune function target and the liver、the kidney function、white blood cell's change,uses the SPSS12.0 statistics software package to carry on the analysis processing。
Results:The treatment group increase in immunity obviously better than the control group(P＜0.05);In narrowing the tumor and reducing effect of AFP broadly similar in both groups(P＞0.05);Intervention in the side-effects,There are not seen the obvious difference between Two groups(P＞0.05)。
Conclusion:Artesunate combined intervention therapy can improve patients with primary liver cancer in the body immunity,increase the involvement of liver damage.To Artesunate anti-tumor clinical research have a certain significance。
引文
[1]王家晓.脾虚与肝癌病因证治关系.中国中西医结合消化杂志,2005,13(1):63-64
[2]刘庆,张彦博,马传红等.原发性肝癌的中医治法与方药.中西医结合学报,2005.3(4):260-262
[3]陈伟,钱力兰,王昌俊等.“钱氏肝癌方”加减治疗53例原发性肝癌临床观察[J].上海中医药杂志,1998,(4):14-16.
[4]林宗广.健脾消症方治疗脾虚型中晚期原发性肝癌36例临床疗效观察[J].中国中西医结合脾胃杂志,1997,5(4):202-204.
[5]刘晓蓉.一贯煎加减在肝癌化疗中的应用[J].南京中医药大学学报,1996,12(2):60.
[6]李泽浩,陈焕朝.健脾通络法治疗中晚期肝癌22例观察[J].肿瘤防治研究,1998,25(5):406-407.
[7]郭士全,刘德生.克木汤治疗原发性肝癌63例临床观察[J].徐州医学院学报,1996,16(4):434-435.
[8]马玉红.中医药治疗晚期肝癌28例临床观察[J].中医杂志,1996,37(1):43.
[9]傅理琦.扶正抑瘤汤治疗晚期肝癌42例临床观察[J].浙江中医杂志,2001,(9):375-376.
[10]冯敢生,颜小琼,王丽雅.中药白芨作为血管栓塞剂的动物实验研究和临床应用.中华放射学杂志,1985;19(4)193-196
[11]陈世唏,庄一平,吴美琦等.鸦胆子油-碘油/阿霉素超液化乳剂治疗中晚期肝癌的研究.江苏医药,1991;17(10)536-538
[12]肖立森,朱为民.榄香烯经肝动脉介入治疗原发性肝癌的临床研究总结.中国肿瘤临床,1996;23(10):757-758
[13]周建芳,宋时国.华蟾素加化学药物动脉灌注治疗原发性肝癌的临床观察.中国中西药结合杂志,1997;11(7):686-687
[14]杨敏一,梁宝英,余清平等.B超导向瘤体中心注射去甲斑蝥素治疗中晚期肝癌41例.人民军医,1993;6(9):44-46
[15]孙钰,沈建华.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究.上海中医药杂志,2000;1:14-15
[16]吴树强,贾勇士.鸦胆子油肝动脉灌注治疗转移性肝癌.中国肿瘤,2004;13(8):523-524
[17]程剑华,刘伟胜.中药介入治疗原发性肝癌16例疗效观察.新中医,1998,30(3):30-31
[18]韩铭钧,任克等.油性中药抗癌剂OCC肝动脉栓塞治疗肝癌84例3年随访报告.临 床放射学杂志,1998;17(2):112-113
[19]叶小卫,周岱翰.羟基喜树碱在肝动脉化疗栓塞术治疗原发性肝癌中的应用.中国肿瘤,1999;31(6):31
[20]李翔武,谷文韬,梁兆玉.羟基喜树碱经肝动脉介入治疗原发性肝癌的临床研究总结.中国肿瘤临床,2000;27(5):396-397
[21]吴哲生,黄瑀.榄香烯乳肝动脉介入治疗肝癌32例.新中医,2001;18(5):66-67
[22]周鸿飞,余振江.蟾酥微球肝动脉栓塞治疗肝癌.现代中西医结合杂志,2000;9(21):2160
[23]吴薏婷.药盒灌注复方苦参注射液联合TACE治疗肝癌的临床观察.中国中医基础医学杂志,2005;11(3):233-234
[24]张华,黄金活,李金昌等.经皮左锁骨下药盒肝动脉灌注拓僖为主治疗晚期肝癌临床分析.中国肿瘤临床与康复,2004;11(5):440-441
[25]叶小卫,陈瑶,周岱翰.中医药在肝癌治疗中的应用及展望.中国肿瘤,2000;9(8):350-351
[26]张华,王清茂.经皮左锁骨下动脉植入药盒系统治疗晚期肝癌.癌症,2000;19(8):792
[27]李金昌.中医辨证配合介入治疗原发性肝癌的临床观察.广东医学,2001;21(3):33-34
[28]贾雨辰.肝癌介入治疗的进展.中国实用外科杂志,1995;15(3):175
[29]杨连粤,黄耿文,黄建华等.114例大肝癌的手术切除.中国实用外科杂志,2002:22(6):353-355
[30]吴孟超,陈汉,沈锋.原发性肝癌的外科治疗5524例报告[J].中华外科杂志,2001:39(6):417-421
[31]芮静安,王少斌,陈曙光等.以手术为主的系列疗法治疗原发性大肝癌(附191例报告).中华肿瘤杂志,2001;23(5):417-419
[32]Fan J,Tang ZY,Yu YQ,et al.Improved survival with resection after transcatheter 青蒿琥酯 erial chemoembolization for unresectable hepatocellular carcinoma.Dig Surg,1998:15:674
[33]Fan J,Tang ZY,Yu YQ,et al.Improved survival with resection after transcatheter 青蒿琥酯 erial chemoembolization for unresectable hepatocellular carcinoma.Dig Surg,1998;15:674
[34]韩有志.肝血管灌注化疗预防大肝癌术后复发的意义.中国实用外科杂志,2000;20(3):137-138
[35]张清泉、胡宗泽、王兴国等.16例生存5年以上不能切除大肝癌的优化综合治疗研究.中华肝胆外科杂志,2000:6(1):36
[36]程红岩,徐爱民,陈栋等.根据大肝癌的血供特点确定介入治疗的碘油剂量.中华肿瘤杂志,2003;25(2):186-189
[37]王平瑜,欧阳贞红,杨家和等.介入治疗时机的选择-在肝癌切除术后预防复发的研究.中国肿瘤临床与康复,2002;9(1):82-84
[38]陈晓明,罗鹏飞,林华欢等.肝癌介入治疗模式的探讨.中华肿瘤杂志,2002:24(5):501-503
[39]陈晓明,罗鹏飞,胡景铃等.肝癌经导管肝动脉碘油抗癌药混悬及栓塞后肝脏的延期不良反应.癌症,1994;13(1):50-53
[40]Groupe d,Etude et al.A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.N Engl J Med.1995 May 11:3(19):1256-61
[41]贾雨辰,田建明,王振堂.为进一步提高肝癌介入治疗的效果而努力.中华放射学杂志,1996;30(2):77
[42]赵荫农,杨南武,袁卫平等.肿瘤血流监测经皮肝动脉门静脉化疗栓塞治疗大肝癌.肝胆外科杂志,1998;6(5):289-290
[43]赵荫农,袁卫平,杨南武等.经肝动脉门静脉化学药物栓塞加手术切除治疗大肝癌48例体会.中华普通外科杂志,2000;15(1):10-11
[44]陈夷.陈汉,吴孟超等.经皮微波热凝治疗肝癌的疗效观察.中华肿瘤杂志,2002:24(1):65-67
[45]Livraghi T,Benedini V,Lazzaroni S,et al.Long-term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma.Cancer,1998:83:48
[46]张智坚,吴孟超,陈汉等.经皮肝穿刺射频热凝治疗肝癌.第二军医大学学报,2001:22(7):669-671
[47]范林军,马宽生,何振平等.射频消融联合肝动脉及选择性门静脉栓塞治疗大肝癌.第三军医大学学报,2002;24(4):447-449
[48]LivraghiT,MeloniF.Treatmentof hepatocellular carcinoma by percutaneou sinterventional methods.Hepatogastro enterology,2002:49(43):62-71
[49]RossiS,BuscariniE,GarbagnatiF,etal.Percutaneous treatment of small hepatic tumors by an expandable RFneedle electrode.ARoentgenol,1998:170:1015-122
[50]GaianiS,CelliN,CecilioniL,etal.Review青蒿琥酯icle:perctaneous treatment of hepatocellular carcinoma.AlimentPha macolTher,2003;17(Supp12):103-110
[51]LivraghiT,GoldbergSN,LazzaroniS,etal.smallhepacellularcarcinoma:treat ment with radio-frequency ablatvers usethanol injection.Radioligy,1999;210:655-661
[52]KurokohchiK,WatanabeS,MasakiT,etal.Combined use of percutaneouse thanol injection andradio frequency ablationfor the effective treatment of hepatocelluar carcinoma.IntJ Oncol,2002:21(4):841-846
[53]Arch-FerrerJE SmithJK,BynonS,etal.Radio- frequency ablation incirrhotic patient with hepatocellular carcinoma.AmSurg 2003;69(12):1067-1071
[54]DongB,LiangP,YuX,etal.Percutaneoussonographicallyguidedmicrowavec oagulation therapy for hepatocellular carcinoma:resultsin 234patients.AmJRoentgenol,2003:180(6):1547-1555
[55]LarsonTR,RrobertsonDW,CoricaA,etal.Invivoint erstitial temperature mapping Of The human prostate during cryosurgerywith correlation tohisto pathologic outcomes.Urology,2000:55(4):547-552
[56]ClavienPA,KangKJ,SelznerN,etal.Cryosurgeryafte Chemoembolization for hepatocellula carcinomain patient with cirrhosis.JGastrointestSurg,2002:6(1):95-10
[57]KengGH,SundramFX.Radionuclide therapy of hepatocellular carcinoma.AnnAcadMed Singapore,2003;32(4):518
[58]李立,严律南,陈晓理等.放射性微球治疗晚期肝癌内照射剂量与疗效关系的探讨.中华放射肿瘤学杂志,1998;7(2):105-108
[59]徐益语,于尔新.自制肝病方治疗原发性肝癌临床疗效观察[J].上海中医杂志。1993。(12):3.
[60]傅凤霞,张正芳,王琦.原发性肝癌术后辨证治疗60例[J].南京中医药大学学报,1997,13(5):314.
[61]季平.补气活血法治疗肝癌术后18例疗效观察[J].河北中医。1998。20(2):84.
[62]刘晓蓉.一贯煎加减在肝癌化疗中的应用[J].南京巾医药大学学报,1996,12(2):60.
[63]陈乃杰,金源.中医辨证配合放射治疗原发性肝癌的临床观察[J].肿瘤,1998,18(4):299.
[64]章永红.补肝软坚汤抗癌增效作用的临床观察[J].湖北中医杂志,1998,(1):21.
[65]李薇,李象霖.扶正抑瘤汤对中晚期原发性肝癌化疗解毒增效作用[J].中国中医药信息杂志。2001,8(5):52-53.
[66]邬晓东,金学军,刘淑梅等.中药护肝软坚方对Ⅱ、Ⅲ期原发性肝癌肝动脉化疗栓塞增效减毒作用观察[J].北京中医药大学学报,2003,2(1):67-68.
[67]苏新华,王勇.大柴胡汤加味治疗肝癌介入栓塞后综合征66例临床观察[J].江苏中医药。2003。24(7):28.
[68]李大鹏,陶岚,王书浩等.六君子汤治疗原发性肝癌介入术后栓塞综合征59例[J].新中医,2004,10:61-62.
[69]袁洪新,于志坚.艾迪注射液联合肝动脉介入治疗原发性肝癌[J].临床肿瘤学杂志,2005,10(1):64-66
[70]邓定安.许承辉,蔡俊超.有抗肿瘤活性的青蒿B衍生物口].药学学报,1992,27(4):317-320.
[71]杨小平,潘启超,梁永钜等.青蒿酯钠的抗肿瘤作用[J].癌症,1997,16(3):186-187.
[72]陈绍芳,徐亦益.刘祥麟等.青蒿琥酯对小鼠肝癌的抑瘤作用[J].中国肿瘤,2004,13(6):375-377.
[73]王胜伟,张仲苗,章荣华.青蒿琥酯抗肿瘤作用观察[J].中药药理与临床,2005,21(5):12-13.
[74]王勤,吴理茂,赵一等.青蒿琥酯抗肿瘤作用的机制研究[J].药学学报.2002:37(6):477-478
[75]吴理茂,李爱媛等.青蒿琥酯抗肝癌作用的实验研究[J].中国中药杂志,2001,26(10):707-708.
[76]Efferth T,Dunstan H,Sauerbrey A,et al.The anti-malarial artesunate is also active against cancer[J].Int J Oncol,2001,18(4):767-773.
[77]陈征途,黄真炎,吴玲霓等.青蒿素介导肝癌细胞凋亡的实验研究[J].中西医结合肝病杂志,2000.10(5):23-25.
[78]吴理茂,赵一,王勤等.青蒿琥酯治疗肝癌的机理初探[J].中国中医基础医学杂志,2000,(8):593-594.
[79]王勤,吴理茂,赵一等.青蒿琥酯抗肿瘤作用的机制研究[J].药学学报,2002,37(6):477-478.
[80]Dell' Eva R,Heifer U,Vene R,et al.Inhibition of angiogenesis in vivoand growth of Kaposi's sarcoma xenograft tumors by the anti-malarialartesunate[J].Biochem Pharmacol,2004,68(12):2359-2366.
[81]Efferth T,sauerbrey A,Olbrich A,et al,Molecular modes of action of artesunate in tumor cell lines[J].Mol -Pharmacol,2003,64(2):382-394
[82]林芳,钱之玉.丁健等.二氢青蒿素对人乳腺癌MCF-7细胞的体外抑制作用[J].中国新药杂志,2002,11(12):934-936.
[83]Ferara N.Houck I,Jakeman L,et al.Molecular and biological properties of the vascular endothelial growth factor[J].J Mol Med, 1999.77(7):527-543.
[84]陈欢欢,周惠君.青蒿琥酯的抗血管生成作用[J].药学学报,2004,39(1):29-33.
[85]DellEva R,Pfeffer U,Vene R,et al.Biochem Pharmacol,2004,68(12):2359-2366
[86]王玮琴,周慧君,陈欢欢,等.青蒿琥酯抑制新生血管生成的作用[J].中国药理学与毒理学杂志,2004,18(1):32-36.
[87]van Agtmael M A,Eggehe T A,van Boxtel C J.Artemisinin drugs inthe treatment of malaria:from medicinal herb to registered medication[J].Trends Pharmacol Sci,1999,20(5):199-205.
[88]Shterman N,Kupfer B,Moroz C.Comparison of transferfin receptors,iron content and isoferritin profile in normal and malignant hurllan breast cell lines[J].Pathobiolugy,1991,59(1):19-25.
[89]Reizenstein P.Iron,free radicals and cancer[J]Med OncolTumor Pharmacother,1991,8(4):229-233.
[90]Raaf H N,Jacobsen D W,Savon S,et al.Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast[J].Am J Clin Pathol,1993,99(3):232-237.
[91]Henry Lai,Narendra P.Singh Selective cancer cell cytotoxicityfrom exposure to dihydroartemisinin and holotransferrin[J].Cancer Letters,1995,1(91):41-46.
[92]Singh N P,Lai H.Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells[J].Life Sci,2001,70(1):49-56.
[93]Efferth T,Benakis A,Romero M R.Enhancement of cytotoxici-ty of artemisinins toward cancer cells by ferrous- iron[J].FreeRadic Biol M ed,2004,7(37):998-1009.
[94]Lai H,Sasaki T,Messay A,et al.Effects of artemisinin-tagged holotransferrin on cancer cells[J].Life Sei,2005,76(11):1267-1279.
[95]张华,王清茂.经皮左锁骨下动脉插管植入药盒系统灌注羟基喜树碱为主治疗晚期肝癌.癌症2000:19(2):792-794
[96]张源才,余上海,张永辉等.超声引导经皮肝穿注射青蒿琥酯治疗原发性肝癌15例[J]实用临床医药杂志.2007:11(2):64-66
[97]肖柳英,林培英,张丹等.青蒿琥酯对小鼠肝癌及S180实体瘤的抑制作用[J].实用癌症杂志2001:16(3):245-247
[98]张祖贻,余世庆,苗立云等.青蒿琥酯联合NP方案治疗中晚期非小细胞肺癌的随机对照研究.《中西医结合学报》.
[99]Cooper M A,Fehniger T A,Caligiuri M A.The biology ofhuman natural killer celsubsets[J].Trends Immunol,2001:22(11):633.640.
[100]孙秀珍,谢蜀生,龙振洲等.青蒿素及其衍生物免疫抑制作用的实验研究.中西医结合杂志,1991:11(1):37-38.
[101]周平,高玉祥.青蒿琥酯对NK细胞活性及ADCC活性的影响[J].蚌埠医学院学报,1995:20(6):363-364.
[102]林培英.青蒿寨、青蒿琥酯和蒿甲醚对抑制性T细胞的作用[J].广州医药,1998:29(1):37
[103]Yang SX,Xie SS,Gao HL,et al.Artemisinin and its derivatives enhance T lymphocyte-mediated immune responses in normal mice and accelerate immunoreconstitution of mice with syngeneic bone ITIaI' TOW transplantation.(31in Immunol Immunopathol,1993,69(2):143-148.
[104]LinPY,FengZM,Pan JQ,et al.Effects of artesunate on immune function in mice.Zhongguo Yao Li Xue Bao,1995;16(5):441-444.
[105]蒲秀瑛,傅宣英,王琪,景涛。青蒿琥酯治疗小鼠继发性棘球蚴病后机体免疫转归及肝脏中部分酶活性的变化。地方病通报.2006:21(1)12-15
[106]Batty KT,Le AT,Ilett KF,et al.Apharmaeokinetie and pharmaeodynamic study of Artesunate for vivaxmalaria 『J1.Am J Trop Med Hyg,1998;59(5):823-827.
[2]刘庆,张彦博,马传红等.原发性肝癌的中医治法与方药.中西医结合学报,2005.3(4):260-262
[3]陈伟,钱力兰,王昌俊等.“钱氏肝癌方”加减治疗53例原发性肝癌临床观察[J].上海中医药杂志,1998,(4):14-16.
[4]林宗广.健脾消症方治疗脾虚型中晚期原发性肝癌36例临床疗效观察[J].中国中西医结合脾胃杂志,1997,5(4):202-204.
[5]刘晓蓉.一贯煎加减在肝癌化疗中的应用[J].南京中医药大学学报,1996,12(2):60.
[6]李泽浩,陈焕朝.健脾通络法治疗中晚期肝癌22例观察[J].肿瘤防治研究,1998,25(5):406-407.
[7]郭士全,刘德生.克木汤治疗原发性肝癌63例临床观察[J].徐州医学院学报,1996,16(4):434-435.
[8]马玉红.中医药治疗晚期肝癌28例临床观察[J].中医杂志,1996,37(1):43.
[9]傅理琦.扶正抑瘤汤治疗晚期肝癌42例临床观察[J].浙江中医杂志,2001,(9):375-376.
[10]冯敢生,颜小琼,王丽雅.中药白芨作为血管栓塞剂的动物实验研究和临床应用.中华放射学杂志,1985;19(4)193-196
[11]陈世唏,庄一平,吴美琦等.鸦胆子油-碘油/阿霉素超液化乳剂治疗中晚期肝癌的研究.江苏医药,1991;17(10)536-538
[12]肖立森,朱为民.榄香烯经肝动脉介入治疗原发性肝癌的临床研究总结.中国肿瘤临床,1996;23(10):757-758
[13]周建芳,宋时国.华蟾素加化学药物动脉灌注治疗原发性肝癌的临床观察.中国中西药结合杂志,1997;11(7):686-687
[14]杨敏一,梁宝英,余清平等.B超导向瘤体中心注射去甲斑蝥素治疗中晚期肝癌41例.人民军医,1993;6(9):44-46
[15]孙钰,沈建华.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究.上海中医药杂志,2000;1:14-15
[16]吴树强,贾勇士.鸦胆子油肝动脉灌注治疗转移性肝癌.中国肿瘤,2004;13(8):523-524
[17]程剑华,刘伟胜.中药介入治疗原发性肝癌16例疗效观察.新中医,1998,30(3):30-31
[18]韩铭钧,任克等.油性中药抗癌剂OCC肝动脉栓塞治疗肝癌84例3年随访报告.临 床放射学杂志,1998;17(2):112-113
[19]叶小卫,周岱翰.羟基喜树碱在肝动脉化疗栓塞术治疗原发性肝癌中的应用.中国肿瘤,1999;31(6):31
[20]李翔武,谷文韬,梁兆玉.羟基喜树碱经肝动脉介入治疗原发性肝癌的临床研究总结.中国肿瘤临床,2000;27(5):396-397
[21]吴哲生,黄瑀.榄香烯乳肝动脉介入治疗肝癌32例.新中医,2001;18(5):66-67
[22]周鸿飞,余振江.蟾酥微球肝动脉栓塞治疗肝癌.现代中西医结合杂志,2000;9(21):2160
[23]吴薏婷.药盒灌注复方苦参注射液联合TACE治疗肝癌的临床观察.中国中医基础医学杂志,2005;11(3):233-234
[24]张华,黄金活,李金昌等.经皮左锁骨下药盒肝动脉灌注拓僖为主治疗晚期肝癌临床分析.中国肿瘤临床与康复,2004;11(5):440-441
[25]叶小卫,陈瑶,周岱翰.中医药在肝癌治疗中的应用及展望.中国肿瘤,2000;9(8):350-351
[26]张华,王清茂.经皮左锁骨下动脉植入药盒系统治疗晚期肝癌.癌症,2000;19(8):792
[27]李金昌.中医辨证配合介入治疗原发性肝癌的临床观察.广东医学,2001;21(3):33-34
[28]贾雨辰.肝癌介入治疗的进展.中国实用外科杂志,1995;15(3):175
[29]杨连粤,黄耿文,黄建华等.114例大肝癌的手术切除.中国实用外科杂志,2002:22(6):353-355
[30]吴孟超,陈汉,沈锋.原发性肝癌的外科治疗5524例报告[J].中华外科杂志,2001:39(6):417-421
[31]芮静安,王少斌,陈曙光等.以手术为主的系列疗法治疗原发性大肝癌(附191例报告).中华肿瘤杂志,2001;23(5):417-419
[32]Fan J,Tang ZY,Yu YQ,et al.Improved survival with resection after transcatheter 青蒿琥酯 erial chemoembolization for unresectable hepatocellular carcinoma.Dig Surg,1998:15:674
[33]Fan J,Tang ZY,Yu YQ,et al.Improved survival with resection after transcatheter 青蒿琥酯 erial chemoembolization for unresectable hepatocellular carcinoma.Dig Surg,1998;15:674
[34]韩有志.肝血管灌注化疗预防大肝癌术后复发的意义.中国实用外科杂志,2000;20(3):137-138
[35]张清泉、胡宗泽、王兴国等.16例生存5年以上不能切除大肝癌的优化综合治疗研究.中华肝胆外科杂志,2000:6(1):36
[36]程红岩,徐爱民,陈栋等.根据大肝癌的血供特点确定介入治疗的碘油剂量.中华肿瘤杂志,2003;25(2):186-189
[37]王平瑜,欧阳贞红,杨家和等.介入治疗时机的选择-在肝癌切除术后预防复发的研究.中国肿瘤临床与康复,2002;9(1):82-84
[38]陈晓明,罗鹏飞,林华欢等.肝癌介入治疗模式的探讨.中华肿瘤杂志,2002:24(5):501-503
[39]陈晓明,罗鹏飞,胡景铃等.肝癌经导管肝动脉碘油抗癌药混悬及栓塞后肝脏的延期不良反应.癌症,1994;13(1):50-53
[40]Groupe d,Etude et al.A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.N Engl J Med.1995 May 11:3(19):1256-61
[41]贾雨辰,田建明,王振堂.为进一步提高肝癌介入治疗的效果而努力.中华放射学杂志,1996;30(2):77
[42]赵荫农,杨南武,袁卫平等.肿瘤血流监测经皮肝动脉门静脉化疗栓塞治疗大肝癌.肝胆外科杂志,1998;6(5):289-290
[43]赵荫农,袁卫平,杨南武等.经肝动脉门静脉化学药物栓塞加手术切除治疗大肝癌48例体会.中华普通外科杂志,2000;15(1):10-11
[44]陈夷.陈汉,吴孟超等.经皮微波热凝治疗肝癌的疗效观察.中华肿瘤杂志,2002:24(1):65-67
[45]Livraghi T,Benedini V,Lazzaroni S,et al.Long-term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma.Cancer,1998:83:48
[46]张智坚,吴孟超,陈汉等.经皮肝穿刺射频热凝治疗肝癌.第二军医大学学报,2001:22(7):669-671
[47]范林军,马宽生,何振平等.射频消融联合肝动脉及选择性门静脉栓塞治疗大肝癌.第三军医大学学报,2002;24(4):447-449
[48]LivraghiT,MeloniF.Treatmentof hepatocellular carcinoma by percutaneou sinterventional methods.Hepatogastro enterology,2002:49(43):62-71
[49]RossiS,BuscariniE,GarbagnatiF,etal.Percutaneous treatment of small hepatic tumors by an expandable RFneedle electrode.ARoentgenol,1998:170:1015-122
[50]GaianiS,CelliN,CecilioniL,etal.Review青蒿琥酯icle:perctaneous treatment of hepatocellular carcinoma.AlimentPha macolTher,2003;17(Supp12):103-110
[51]LivraghiT,GoldbergSN,LazzaroniS,etal.smallhepacellularcarcinoma:treat ment with radio-frequency ablatvers usethanol injection.Radioligy,1999;210:655-661
[52]KurokohchiK,WatanabeS,MasakiT,etal.Combined use of percutaneouse thanol injection andradio frequency ablationfor the effective treatment of hepatocelluar carcinoma.IntJ Oncol,2002:21(4):841-846
[53]Arch-FerrerJE SmithJK,BynonS,etal.Radio- frequency ablation incirrhotic patient with hepatocellular carcinoma.AmSurg 2003;69(12):1067-1071
[54]DongB,LiangP,YuX,etal.Percutaneoussonographicallyguidedmicrowavec oagulation therapy for hepatocellular carcinoma:resultsin 234patients.AmJRoentgenol,2003:180(6):1547-1555
[55]LarsonTR,RrobertsonDW,CoricaA,etal.Invivoint erstitial temperature mapping Of The human prostate during cryosurgerywith correlation tohisto pathologic outcomes.Urology,2000:55(4):547-552
[56]ClavienPA,KangKJ,SelznerN,etal.Cryosurgeryafte Chemoembolization for hepatocellula carcinomain patient with cirrhosis.JGastrointestSurg,2002:6(1):95-10
[57]KengGH,SundramFX.Radionuclide therapy of hepatocellular carcinoma.AnnAcadMed Singapore,2003;32(4):518
[58]李立,严律南,陈晓理等.放射性微球治疗晚期肝癌内照射剂量与疗效关系的探讨.中华放射肿瘤学杂志,1998;7(2):105-108
[59]徐益语,于尔新.自制肝病方治疗原发性肝癌临床疗效观察[J].上海中医杂志。1993。(12):3.
[60]傅凤霞,张正芳,王琦.原发性肝癌术后辨证治疗60例[J].南京中医药大学学报,1997,13(5):314.
[61]季平.补气活血法治疗肝癌术后18例疗效观察[J].河北中医。1998。20(2):84.
[62]刘晓蓉.一贯煎加减在肝癌化疗中的应用[J].南京巾医药大学学报,1996,12(2):60.
[63]陈乃杰,金源.中医辨证配合放射治疗原发性肝癌的临床观察[J].肿瘤,1998,18(4):299.
[64]章永红.补肝软坚汤抗癌增效作用的临床观察[J].湖北中医杂志,1998,(1):21.
[65]李薇,李象霖.扶正抑瘤汤对中晚期原发性肝癌化疗解毒增效作用[J].中国中医药信息杂志。2001,8(5):52-53.
[66]邬晓东,金学军,刘淑梅等.中药护肝软坚方对Ⅱ、Ⅲ期原发性肝癌肝动脉化疗栓塞增效减毒作用观察[J].北京中医药大学学报,2003,2(1):67-68.
[67]苏新华,王勇.大柴胡汤加味治疗肝癌介入栓塞后综合征66例临床观察[J].江苏中医药。2003。24(7):28.
[68]李大鹏,陶岚,王书浩等.六君子汤治疗原发性肝癌介入术后栓塞综合征59例[J].新中医,2004,10:61-62.
[69]袁洪新,于志坚.艾迪注射液联合肝动脉介入治疗原发性肝癌[J].临床肿瘤学杂志,2005,10(1):64-66
[70]邓定安.许承辉,蔡俊超.有抗肿瘤活性的青蒿B衍生物口].药学学报,1992,27(4):317-320.
[71]杨小平,潘启超,梁永钜等.青蒿酯钠的抗肿瘤作用[J].癌症,1997,16(3):186-187.
[72]陈绍芳,徐亦益.刘祥麟等.青蒿琥酯对小鼠肝癌的抑瘤作用[J].中国肿瘤,2004,13(6):375-377.
[73]王胜伟,张仲苗,章荣华.青蒿琥酯抗肿瘤作用观察[J].中药药理与临床,2005,21(5):12-13.
[74]王勤,吴理茂,赵一等.青蒿琥酯抗肿瘤作用的机制研究[J].药学学报.2002:37(6):477-478
[75]吴理茂,李爱媛等.青蒿琥酯抗肝癌作用的实验研究[J].中国中药杂志,2001,26(10):707-708.
[76]Efferth T,Dunstan H,Sauerbrey A,et al.The anti-malarial artesunate is also active against cancer[J].Int J Oncol,2001,18(4):767-773.
[77]陈征途,黄真炎,吴玲霓等.青蒿素介导肝癌细胞凋亡的实验研究[J].中西医结合肝病杂志,2000.10(5):23-25.
[78]吴理茂,赵一,王勤等.青蒿琥酯治疗肝癌的机理初探[J].中国中医基础医学杂志,2000,(8):593-594.
[79]王勤,吴理茂,赵一等.青蒿琥酯抗肿瘤作用的机制研究[J].药学学报,2002,37(6):477-478.
[80]Dell' Eva R,Heifer U,Vene R,et al.Inhibition of angiogenesis in vivoand growth of Kaposi's sarcoma xenograft tumors by the anti-malarialartesunate[J].Biochem Pharmacol,2004,68(12):2359-2366.
[81]Efferth T,sauerbrey A,Olbrich A,et al,Molecular modes of action of artesunate in tumor cell lines[J].Mol -Pharmacol,2003,64(2):382-394
[82]林芳,钱之玉.丁健等.二氢青蒿素对人乳腺癌MCF-7细胞的体外抑制作用[J].中国新药杂志,2002,11(12):934-936.
[83]Ferara N.Houck I,Jakeman L,et al.Molecular and biological properties of the vascular endothelial growth factor[J].J Mol Med, 1999.77(7):527-543.
[84]陈欢欢,周惠君.青蒿琥酯的抗血管生成作用[J].药学学报,2004,39(1):29-33.
[85]DellEva R,Pfeffer U,Vene R,et al.Biochem Pharmacol,2004,68(12):2359-2366
[86]王玮琴,周慧君,陈欢欢,等.青蒿琥酯抑制新生血管生成的作用[J].中国药理学与毒理学杂志,2004,18(1):32-36.
[87]van Agtmael M A,Eggehe T A,van Boxtel C J.Artemisinin drugs inthe treatment of malaria:from medicinal herb to registered medication[J].Trends Pharmacol Sci,1999,20(5):199-205.
[88]Shterman N,Kupfer B,Moroz C.Comparison of transferfin receptors,iron content and isoferritin profile in normal and malignant hurllan breast cell lines[J].Pathobiolugy,1991,59(1):19-25.
[89]Reizenstein P.Iron,free radicals and cancer[J]Med OncolTumor Pharmacother,1991,8(4):229-233.
[90]Raaf H N,Jacobsen D W,Savon S,et al.Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast[J].Am J Clin Pathol,1993,99(3):232-237.
[91]Henry Lai,Narendra P.Singh Selective cancer cell cytotoxicityfrom exposure to dihydroartemisinin and holotransferrin[J].Cancer Letters,1995,1(91):41-46.
[92]Singh N P,Lai H.Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells[J].Life Sci,2001,70(1):49-56.
[93]Efferth T,Benakis A,Romero M R.Enhancement of cytotoxici-ty of artemisinins toward cancer cells by ferrous- iron[J].FreeRadic Biol M ed,2004,7(37):998-1009.
[94]Lai H,Sasaki T,Messay A,et al.Effects of artemisinin-tagged holotransferrin on cancer cells[J].Life Sei,2005,76(11):1267-1279.
[95]张华,王清茂.经皮左锁骨下动脉插管植入药盒系统灌注羟基喜树碱为主治疗晚期肝癌.癌症2000:19(2):792-794
[96]张源才,余上海,张永辉等.超声引导经皮肝穿注射青蒿琥酯治疗原发性肝癌15例[J]实用临床医药杂志.2007:11(2):64-66
[97]肖柳英,林培英,张丹等.青蒿琥酯对小鼠肝癌及S180实体瘤的抑制作用[J].实用癌症杂志2001:16(3):245-247
[98]张祖贻,余世庆,苗立云等.青蒿琥酯联合NP方案治疗中晚期非小细胞肺癌的随机对照研究.《中西医结合学报》.
[99]Cooper M A,Fehniger T A,Caligiuri M A.The biology ofhuman natural killer celsubsets[J].Trends Immunol,2001:22(11):633.640.
[100]孙秀珍,谢蜀生,龙振洲等.青蒿素及其衍生物免疫抑制作用的实验研究.中西医结合杂志,1991:11(1):37-38.
[101]周平,高玉祥.青蒿琥酯对NK细胞活性及ADCC活性的影响[J].蚌埠医学院学报,1995:20(6):363-364.
[102]林培英.青蒿寨、青蒿琥酯和蒿甲醚对抑制性T细胞的作用[J].广州医药,1998:29(1):37
[103]Yang SX,Xie SS,Gao HL,et al.Artemisinin and its derivatives enhance T lymphocyte-mediated immune responses in normal mice and accelerate immunoreconstitution of mice with syngeneic bone ITIaI' TOW transplantation.(31in Immunol Immunopathol,1993,69(2):143-148.
[104]LinPY,FengZM,Pan JQ,et al.Effects of artesunate on immune function in mice.Zhongguo Yao Li Xue Bao,1995;16(5):441-444.
[105]蒲秀瑛,傅宣英,王琪,景涛。青蒿琥酯治疗小鼠继发性棘球蚴病后机体免疫转归及肝脏中部分酶活性的变化。地方病通报.2006:21(1)12-15
[106]Batty KT,Le AT,Ilett KF,et al.Apharmaeokinetie and pharmaeodynamic study of Artesunate for vivaxmalaria 『J1.Am J Trop Med Hyg,1998;59(5):823-827.